Wednesday, March 5, 2014

March HCV Newsletters: Comparison Of Sovaldi And Olysio

Top of the mornin to ya!

March is full of wonderful events, such as Saint Patrick's Day, spring and of course, this months "HCV Newsletters."  As always, these newsletters are brought to you by a small group of individuals devoted to bringing awareness and information to people living with this serious disease. 

Hepatitis C Newsletters

Each awesome publication offers something special for everyone. Hot topics include both newly FDA approved drugs Sovaldi and Olysio, investigational agents currently in clinical trials, personal stories of triumph, even a free online course with videos and easy to understand narration.

Enjoy!



The Hepatitis Foundation International is dedicated to liver health and the prevention of liver related diseases. We inform and educate by making available reliable and up-to-date facts. We want you to make well-informed decisions for yourself and your loved ones' health and well-being. We are proud to present this website as your personal Internet gateway to hepatitis information and liver care.

Hepatitis Foundation International 


In This Issue Of Health-e Bytes

HFI In The Know
Summits, Events, Health Observances 

Lifestyle
Diverse Health Issues 
Krokodil – Poor Man's Heroin

Grand Rounds
Comparison Of Sovaldi™And Olysio™
Improving Life Expectancy With New Antiretroviral Therapy
Science, Research and Medical Updates

In The Pipeline
Clinical Trials and New Drugs
Encouraging News For Treatment Of NASH

T.I.P.S.
Free Resources

And more............

Stay Updated



 




HepCBC’s MONTHLY NEWSLETTER

The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.

Things are changing extremely rapidly with the upcoming new HCV drugs! For the most current news between monthly bulletins, be sure to check out HepCBC NEWS

Important

Show your support for the rights of HCV+ people to live free of discrimination and to access appropriate healthcare.

In This Issue

Sanjiv's Story: 6th attempt at treatment successful!
Read and Sign Brenda Peever's Petition!
Tell Canadian government why they should make DAAs accessible and affordable to all ill patients ASAP!
Upcoming sofosbuvir/ledipasvir trials in Canada
Great new HCV film: DEAL WITH IT
Update on HCV Manifesto and Marathon projects
HepCBC Volunteers at Canadian Digestive Diseases Week
Anti-Depressants plus HCV
STRIDE with PURPOSE Society Information (Lower Mainland BC)
FRENCH Support from CAPAHC in Quebec!
Conferences, Medication Assistance, Compensation
HCV Support Groups in Canada
AND MORE!!


Stay Connected



Canadian Liver Foundation

Free Online Course about Hepatitis C
In partnership with the BC Centre for Disease Control (BCCDC), we are pleased to offer you Hepatitis C: The Basics,  a free online course that covers basic information about hepatitis C.  It is intended for those living with hepatitis C, whether newly diagnosed or having lived with it for a number of years.

This self-paced course includes videos and plain language narration.

http://learn.phsa.ca/bccdc/hepc/player.html

To access the course:
1. Click the “Go for Care” image on the right.
2. After a new window opens, click 'Start Course'

Canadian Liver Foundation’s Newsroom

Newsletter
Livewell is our e-newsletter exclusively for friends and donors of the Canadian Liver Foundation. Each issue highlights liver health issues, exciting research projects, upcoming events and includes profiles of our outstanding volunteers and donors.

The Livewell newsletter is distributed 4x per year. Please click here to fill in the form and we will be happy to add you to our subscriber list!

CLF updates you and interacts with you on all things liver

Stay Updated


http://www.hcvadvocate.org/index.asp

The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.  

HCV Advocate Launches "The HCV Advocate Daily"

The HCV Advocate has launched a tool to keep our readers up to date on the latest information about HCV. HCV Advocate Daily picks up news articles, provides a brief description of the story and a link to the entire article.  We hope that you will take advantage of this exciting new feature. 

HCV Advocate News & Pipeline Blog
Click Here

HCV Advocate Newsletter
March 2014

In This Issue:

Alan Franciscus, Editor-in-Chief


Alan Franciscus, Editor-in-Chief


Lucinda K. Porter, RN

Alan Franciscus, Editor-in-Chief

Alan Franciscus, Editor-in-Chief

HCV Advocate Eblast

HBV Journal Review:  
March 1, 2014, Vol 11, no 3, by Christine Kukka
 
In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including:

Tenofovir More Potent Than Entecavir in Patients with High Viral Loads;
Antiviral Treatment After Liver Cancer Surgery Improves Survival Dramatically
The New "Normal" ALT Levels Are Better at Diagnosing Active Infections
Culturally-Adept Program Boosts HBV Screening Among Asian-Americans
Experts Explore Ways to Treat and Monitor HBeAg-Negative Patients
CDC Experts Estimates 6.5 New Hepatitis B Infections for Every One Reported
Sperm Washing Successfully Prevents Infection Transmittal During Conception
Tenofovir Effective in Patients with Drug Resistance, But Less So with Adefovir-Resistance
Hepatitis B Vaccination Still Protects Even When Antibodies Decline

Connect With HCV Advocate


 
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.

NYC Viral Hepatitis Monthly E-Newsletter


In This Issue

March 20 (8 - 3:30) Harlem Hospital Center.

 
Andrew Styles

I am the first patient at Mount Sinai Hospital’s IMA Primary Care Hepatitis C clinic to start the newest treatment to cure HCV (using sofosbuvir/ interferon/ ribavirin). 
My first injection was on January 15, 2014 and my treatment will end on April 9, 2014 (only 12 weeks!).

And more.......

Subscribe to this Newsletter

Join Us


Hepatitis C news, is an online community for those living with hepatitis C. Join us for news, views and features about hep C, read the real-life experiences of our guest bloggers, and learn about living well with the condition.

New @ Hepatitis C News 

February 26th, 2014
Despite the most advanced healthcare expertise in the world, HCV continues to be a significant problem in the US.

February 25th, 2014 - Written by Karen Hoyt
Brain fog with hepatitis C and cirrhosis, in case you hadn’t noticed, are like peas and carrots, shoes and socks, spring and flowers.
Treatments for hep C –These drugs can leave you like a space cadet! The brain fog I live with now is nothing compared to what I experienced on Telaprevir, Interferon, and Ribavirin. If you are taking Victrelis, Boceprevir, or Sofosbuvir I think the results are the same regarding mental impairment. (That’s a clinical sounding term for brain fog)

Hep C TV
Another monthly round-up of all things hepatitis C. Brought to you by Hepatitis C News.



Stay connected




A monthly newsletter from the National Institutes of Health, part of the U.S. Department of Health and Human Services

In This Issue

 March Features

Your Liver Delivers Protect It From Harm
Your liver works hard to protect your health.
But alcohol, drugs, viruses, and excess weight can damage your liver.

Learn how to help keep your liver healthy for a lifetime. 
Read more about liver health and disease.

Headache Pain
What To Do When Your Head Hurts

Most of us get headaches from time to time. Some are mild. Others cause throbbing pain. They can last for minutes or days. How you treat a headache depends on which kind you have.  

COPD is a serious lung disease that makes it hard to breathe. It’s a leading cause of death in the United States. Many people with COPD don’t realize they have a disease. Learn more about how to spot and treat COPD. Get printable fact sheets, and find COPD-related events and networks that may be in your neighborhood or online.

Find Us On Facebook



Caring Ambassadors Hepatitis C

The Caring Ambassadors Hepatitis C Program (CAP-Hepatitis C) is a national non-profit organization devoted exclusively to meeting the needs of the hepatitis C community.

Monthly Pubmed Review is a collection of the most relevant research on hepatitis C.
View All Monthly Literature Reviews At  CAP Hepatitis C Literature Review 

By Regina Boyle Wheeler Reviewed by Farrokh Sohrabi, MD

Dietrich’s doctor at the time wanted him to start interferon-based hepatitis C therapy right away, in hopes of eliminating the virus. But back in 1999, he said, the success rate was low, and the treatments were said to be worse than the disease.

Dietrich thought he could wait because hepatitis C progresses slowly in most people. Instead, he tried a drastic change in lifestyle to try to prevent liver damage and possibly rid his body of the virus. He cut out all alcohol because it can accelerate cirrhosis, especially in those with hepatitis C. Fried foods, coffee, red meat, artificial sweeteners, and the like were also out. Fruits, veggies, lean meats, and fish were in.
Continue reading.......


GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.

View Current Issue (VOL. 8 NO. 2 February 2014): PDF | Interactive Issue
Check back for March Newsletter

COMMENTARY – The price and cost of hepatitis C treatment
Chronic hepatitis C virus infection is a major cause of liver disease, affecting 180 million
people globally.

Stay connected



 

American Liver Foundation

Liver Lowdown is the monthly general interest e-newsletter of the American Liver Foundation.

In accordance with the Foundation’s mission, the e-newsletter is disseminated to provide information about the prevention, treatment and cure of liver disease, as well as the organization’s research and advocacy endeavors.

Content includes updates about the Foundation’s educational and signature programs; an in-depth focus on specific types of liver disease, and profiles of liver patients’ and caregivers’ personal experiences.

Published Feb 28 - February Newsletter - Check back for March Newsletter

Welcome to the February 2014 edition of the Liver Lowdown. Click on the links below and check out our featured stories for the month!

FEATURE
Hepatitis C and Baby Boomers
If you are a baby boomer, you are at risk for hepatitis C. Of the more than 3 million Americans who have hepatitis C, more than 75% were born between 1945 and 1965.

Core Programs
Our core programs are tailored for people of all ages, whether they are living with or at risk for liver disease. The American Liver Foundation® (ALF) implements a variety of education programs about liver health and wellness and ways to prevent, treat and live with liver disease.

HE Webinar
On January 23, 2014, more than 300 people tuned in to the American Liver Foundation's webinar on hepatic encephalopathy (HE); the first of a four-part webinar series ALF will be presenting on a variety of liver disease topics.

Liver Life Challenge: Disney Run
Thirty people from around the country ran nearly 754 miles collectively and raised $106,944 to support the American Liver Foundation®. The ALF Liver Life Challenge®, part of the annual Walt Disney World® Marathon Weekend, took place January 8-12th in Orlando, Florida. Proceeds benefit ALF's national and regional programs.

ALF Patient Resources
The American Liver Foundation® has a wealth of information about liver disease prevention, screening/testing and treatment.

5 Ways to Love Your Liver
You only have one liver, yet most people don't give much thought to their livers and the vital function it serves. The good news is that you can protect yourself. Here are 5 ways.

Check Us Out On Twitter and Facebook
 .
 Twitter  Facebook

New In March

The Annual Conference on Retroviruses and Opportunistic Infections
March 3 - 6, 2014
Boston, Massachusetts
Clinical researchers gather to share research focused on  HIV/AIDS, and related infectious disease including hepatitis C. 
Links provided to in-depth coverage and media updates updates, here.

An Update: Treat Hepatitis C Now Or Wait? 
To usher in March, we have a collection of slides which offer SVR rates on both FDA approved and investigational agents, including interferon-free regimens in late stage clinical trials. A few other topics touch on off-label use by combining two newly approved drugs, terminology used to determine treatment response and links to relevant information. The slide-set is best viewed in full screen mode, please click here to begin.

Hepatitis C virus: Here comes all-oral treatment 
In this article, we discuss the results of the trials that established the efficacy and safety of sofosbuvir and simeprevir and led to their FDA approval. We also summarize the importance of these agents and evaluate other direct-acting antivirals currently in the pipeline for HCV treatment.
Continue reading here....

Gilead’s Sovaldi Price Limiting State Medicaid Approvals
Costly New Hepatitis C Drug Raises Questions About Who Will Pay
New hepatitis C medication presents a dilemma for Medicaid and other insurers, who must balance the cost against the large numbers of people who might benefit. The $84,000 cost for the cure over 12 weeks, the most expensive medicine for the disease, has states from Pennsylvania to Colorado limiting its use to only the sickest patients, according to health officials and private insurers that manage care for Medicaid programs.

In Case You Missed It

Short Guide to Hepatitis C

2014 Pocket reference especially devoted to hepatitis C

Short Guide to Hepatitis C, which is an expansion and update of the HCV chapters in Hepatology A Clinical Textbook (2014), also published by Flying Publisher. This web based free of charge concept is made possible by unrestricted educational grants from the pharmaceutical industry and has allowed the material to reach countries usually not covered by print media.
Download here.......

May you have the luck of the Irish all this month! Stay well.

Tina

No comments:

Post a Comment